New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies
作者:Nehad A. El-Sayed、Mai S. Nour、M. Alaraby Salem、Reem K. Arafa
DOI:10.1016/j.ejmech.2019.111693
日期:2019.12
subjected to cytotoxic screening against UO-31 renal cancer cell line using MTT assay. Compounds IIId, IX and XIIa displayed promising behavior by showing good anticancer activity. Moreover, kinase inhibitory assay against the tyrosine kinase EGFR was performed for the three compounds showing the highest cytotoxic activity. The tested compounds were potent against EGFR with the highest activity being observed
新型杂环恶二唑,即。2-取代5-(4-吡啶基)-1,3,4-恶二唑,2-取代5-(3-吡啶基)-1,3,4-恶二唑和2-取代5-(苯基或4 -氯苯基-1,3,4-恶二唑被设计并合成为潜在的抗癌药。在这项研究中,由于新的治疗方法假定了与选择性COX-2抑制相关的细胞毒性作用,因此在体外评估了所有化合物的COX-1和COX-2抑制活性。结果表明,与标准消炎痛,双氯芬酸钠和塞来昔布相比,大多数衍生物均表现出对COX两种同工型的抑制作用。然后,使用MTT测定法,对九种选择的化合物(IIId,VIb,VIIc,IX,XI,XIIa,XIVa,XVIb和XVIIIb)进行针对UO-31肾癌细胞系的细胞毒性筛选。化合物IIId,IX和XIIa通过显示出良好的抗癌活性而显示出有希望的行为。此外,针对显示最高细胞毒性活性的三种化合物,进行了针对酪氨酸激酶EGFR的激酶抑制试验。所测试的化合物对EGFR有效,